Clinical Trial Update: A Multi-center Trial to Determine if Curosurf® Reduces the Duration of Mechanical Ventilation in Very Preterm Infants [Phase 3]

View source ↗

Summary

A Phase 3, multi-center trial assessed whether Curosurf (poractant alfa) reduces the duration of mechanical ventilation in very preterm infants with Respiratory…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Curosurf (poractant alfa)

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: Respiratory Distress Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2017-10-25